Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Demant (OtherWILLF) and Tenet Healthcare (THC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on BridgeBio Pharma (BBIO – Research Report), Demant (WILLF – Research Report) and Tenet Healthcare (THC – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BridgeBio Pharma (BBIO)
In a report released today, Jason Zemansky from Bank of America Securities reiterated a Buy rating on BridgeBio Pharma, with a price target of $88.00. The company’s shares closed last Monday at $78.24.
According to TipRanks.com, Zemansky is a 5-star analyst with an average return of
BridgeBio Pharma has an analyst consensus of Strong Buy, with a price target consensus of $95.75, representing a 25.2% upside. In a report issued on January 27, Barclays also initiated coverage with a Buy rating on the stock with a $157.00 price target.
See today’s best-performing stocks on TipRanks >>
Demant (WILLF)
Morgan Stanley analyst Aisyah Noor maintained a Hold rating on Demant today and set a price target of DKK221.00. The company’s shares closed last Monday at $36.53, close to its 52-week low of $35.75.
According to TipRanks.com, Noor is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Demant with a $40.02 average price target.
Tenet Healthcare (THC)
In a report released today, Craig Hettenbach from Morgan Stanley maintained a Buy rating on Tenet Healthcare, with a price target of $247.00. The company’s shares closed last Monday at $188.03.
Hettenbach has an average return of
According to TipRanks.com, Hettenbach is ranked #3130 out of 12040 analysts.
Tenet Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $242.78, representing a 28.0% upside. In a report issued on January 22, RBC Capital also maintained a Buy rating on the stock with a $252.00 price target.
